The National Organization for Rare Disorders (NORD), a nonprofit organization dedicated to supporting those with rare diseases, has launched new patient assistance programs for people with myasthenia gravis (MG) living in the U.S. The new assistance programs aim to help patients who have limited financial resources with…
Argenx has filed an application to the U.S. Food and Drug Administration (FDA) requesting the approval of efgartigimod (ARGX-113) to treat generalized myasthenia gravis (gMG). Similar approval requests are on track to be filed in Europe and Japan this year, Argenx stated in a recently released corporate update.
Quality of life tends to be poorer in people with myasthenia gravis (MG) who develop the disease later in life, have more severe symptoms and little physical activity, or are either overweight or obese, a study found. Life quality tended to be better for those who exercise regularly, have…
Older patients with myasthenia gravis (MG) who receive treatment with intravenous immunoglobulin (IVIG) may be at a higher risk of developing coronary spastic angina, known as CSA, according to a recent case report. In CSA, muscle spasms in the walls of the coronary arteries can block blood…
Johnson & Johnson will acquire Momenta Pharmaceuticals, which has been developing nipocalimab (M281) for the treatment of myasthenia gravis (MG). The process, which involves an all-cash deal totaling about $6.5 billion, is expected to be completed before the end of this year. The acquisition will enable…
High levels of kappa free light chain — a protein that makes up a portion of immunoglobulins (antibodies) — in the bloodstream may indicate the presence of myasthenia gravis (MG) in patients who are harder to diagnose, a study has found. That includes those testing negative…
Soliris (eculizumab) may be a promising treatment option for patients with refractory myasthenia gravis (MG) associated with a tumor in the thymus gland, a case report suggests. The case report study, “Eculizumab as a promising treatment in thymoma-associated myasthenia gravis,” was published in…
Immunovant is preparing to launch a Phase 3 trial of its investigational candidate IMVT-1401 in patients with myasthenia gravis (MG); it may lead to the treatment’s approval for this indication, pending positive results. The new trial will build on data from two previous studies of other drug candidates…
Defects in mitophagy — the process that degrades defective mitochondria, the cell compartments responsible for producing energy — in certain types of immune cells may cause myasthenia gravis (MG), a study contends. The findings also suggest that an antibiotic with immunosuppressant properties, called rapamycin, holds promise…
Rituximab seems to be more effective in newly-diagnosed patients with generalized myasthenia gravis (gMG), compared to people at more advanced stages of the disease, a study has found. Investigators also noted that among newly-diagnosed patients, rituximab seems to be superior to other conventional immunosuppressive regimens. The study, “…
Get regular updates to your inbox.